Skip to main content
SpringerLink
Log in

The Vulnerable Brain: Biological Factors in the Diagnosis and Treatment of Depression

  • Chapter
Psychiatric Diagnosis

Abstract

Psychiatrists can lay no claim to a rich tradition in classification. They have long looked down on classification as a futile activity and a dangerous one to boot, one suggesting that a “labeling” of patients disregards that which is “essential” for them. This view is, of course, untenable. A scientific study should be preceded by a classification of the phenomena on which it focuses. Classification is the foundation of diagnosis and, without adequate diagnosis, treatment as well as research inevitably gives botched results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asberg, M., Bertilsson, L., Tuck, D., Cronholm, B., & Sjöqvist, F. Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin. Pharmacol. Ther., 14, 277–286, 1972.

    Google Scholar 

  2. Asberg, M., Thorén, P., Träskman, L., Bertilsson, L., & Ringberger, V. Serotonin depression—a biochemical subgroup within the affective disorders? Science, 191, 478–480, 1976.

    Article  CAS  PubMed  Google Scholar 

  3. Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Sharman, D. F., McDougall, E. J., Stanton, J. B., & Binns, J. K. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet, 2, 1049–1052, 1966.

    Article  CAS  PubMed  Google Scholar 

  4. Beckmann, H., & Goodwin, F. K. Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Archives of General Psychiatry, 82, 17–21, 1975.

    Article  Google Scholar 

  5. Bertilsson, L., Asberg, M., & Thorén, P. Differential effect of chlorimipramine and nortriptyline on metabolites of serotonin and noradrenaline in the cerebrospinal fluid of depressed patients. European Journal of Clinical Pharmacology, 7, 365–368, 1974.

    Article  CAS  PubMed  Google Scholar 

  6. Blaschko, H., Burn, J. H., & Langemann, H. The formation of noradrenaline from dihydroxyphenylserine. British Journal of Pharmacology, 5, 431–437, 1950.

    CAS  Google Scholar 

  7. Bourne, H. R., Bunney, W. E., Jr., Colburn, R. W., Davis, J. M., Davis, J. N., Shaw, D. M., & Coppen A. J. Noradrenaline, 5-hydroxytryptamine and 5hydroxyindoleacetic acid in hindbrain of suicidal patients. Lancet, 2, 805–808, 1968.

    Article  CAS  PubMed  Google Scholar 

  8. Bowers, M. B., Jr. Deficient transport mechanism for the removal of acid monoamine metabolites from cerebrospinal fluid. Brain Research, 15, 522–524, 1969.

    Article  CAS  PubMed  Google Scholar 

  9. Bowers, M. B., Jr. Cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) following probenecid in unipolar depressives treated with amitriptyline. Psychopharmacologia (Berl.), 23, 26–33, 1972.

    CAS  Google Scholar 

  10. Brodie, H. K. H., Murphy, D. L., Goodwin, F. K., Sc Bunney, W. E., Jr. Catecholamines and mania: The effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clinical Pharmacology and Therapy, 12, 219–224, 1971.

    Google Scholar 

  11. Brodie, H. K. H., Sack, R., & Siever, L. Clinical studies of 5-hydroxytryptophan in depression. In: Barchas, J. and Usdin, E. (Eds.), Serotonin and Behavior. New York: Academic Press, 1973, pp. 549–559.

    Google Scholar 

  12. Butcher, L. L., & Engel, J. Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition. Brain Research, 15, 233–242, 1969.

    Article  CAS  PubMed  Google Scholar 

  13. Buus Lassen, J., Squires, R. F., Christensen, J. A., & Molander, L. Neurochemical and pharmacological studies on a new 5-HT-uptake inhibitor, F6 4963, with potential antidepressant properties. Psychopharmacologia, 42, 21–26, 1975.

    Google Scholar 

  14. Carlsson, A., Corrodi, H., Fuxe, K., & Hökfelt, T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-a-ethyl-meta-tyramine. European Journal of Pharmacology, 5, 357–366, 1969. (a)

    Google Scholar 

  15. Carlsson, A., Corrodi, H., Fuxe, K., & Hökfelt, T. Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4, a-dimethyl-meta-tyramine. European Journal of Pharmacology, 5, 367–373, 1969. (b)

    Article  CAS  PubMed  Google Scholar 

  16. Carroll, B. J., Mowbray, R. M., & Davis, B. M. Sequential comparison of 1-tryptophan with E.C.T. in severe depression. Lancet, 1, 967–969, 1970.

    Article  CAS  PubMed  Google Scholar 

  17. Coppen, A., Shaw, D. M., & Farrell, J. P. Potentiation of the antidepressive effects of a monoamine oxidase inhibitor by tryptophan. Lancet, 1, 79–81, 1963.

    Article  CAS  PubMed  Google Scholar 

  18. Coppen, A., Shaw, D. M., Herzberg, B., & Maggs, R. Tryptophan in treatment of depression. Lancet, 2. 1178–1180, 1967.

    Article  CAS  PubMed  Google Scholar 

  19. Coppen, A., Brooksbank, B. W. L., & Peet, M. Tryptophan concentration in the cerebrospinal fluid of depressive patients. Lancet, 1, 1393, 1972.

    Article  CAS  PubMed  Google Scholar 

  20. Deleon-Jones, F., Maas, J. W., & Dekirmenjian, H. Urinary catecholamine metabolites during behavioral changes in a patient with manic-depressive cycles. Science, 179, 300–302, 1973.

    Article  Google Scholar 

  21. Deleon-Jones, F., Maas, J. W., Dekirmenjian, H., & Sanchez, J. Diagnostic subgroups of affective disorders and their urinary excretion of catecholamine metabolites. American Journal of Psychiatry, 132, 1141–1148, 1975.

    Article  CAS  PubMed  Google Scholar 

  22. Dunner, D. L. & Goodwin, F. K. Effect of 1-tryptophan on brain serotonin metabolism in depressed patients. Archives of General Psychiatry, 26, 364–366, 1972.

    Article  CAS  PubMed  Google Scholar 

  23. Engelman, K., Lovenberg, W., & Sjoerdsma, A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. New England Journal of Medicine, 277, 1103–1108, 1967.

    Article  CAS  PubMed  Google Scholar 

  24. Fawcett, J., Maas, J. W., & Dekirmenjian, H. Depression and MHPG excretion: Response to dextroamphetamine and tricyclic antidepressants. Archives of General Psychiatry, 26, 246–251, 1972.

    Article  CAS  PubMed  Google Scholar 

  25. Feighner, J. P., Robbins, E., Guze, S. B., Woodruff, R. A., Jr., Winokur, G., & Munoz, R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63, 1972.

    Article  CAS  PubMed  Google Scholar 

  26. Fieve, R. R., Platman, S. R., & Fliess, J. L. A clinical trial of methysergide and lithium in mania. Psychopharmacologica, 15, 425–429, 1969.

    Article  CAS  Google Scholar 

  27. Fuller, R. W., Perry, K. W., & Molloy, B. B. Effect of an uptake inhibitor or serotonin metabolism in rat brain: Studies with 3- (p-trifluoromethylphenoxy)-Nmethyl-3-phenylpropylamine (Lilly 110140). Life Science, 15, 1161–1171, 1974.

    Article  CAS  Google Scholar 

  28. Fuller, R. W. & Molloy, B. B. Recent studies with 4-chloroamphetamine and some analogues. Advances in Biochemical Psychopharmacology, 19, 195–205, 1974.

    Google Scholar 

  29. Garelis, E., Young, S. N., Lal, S., & Sourkes, T. L. Monoamine metabolites in lumbar CSF: The question of their origin in relation to clinical studies. Brain Research, 79, 1–8, 1974.

    Article  CAS  PubMed  Google Scholar 

  30. Gershon, S., Hekimian, L. J., Floyd, A., Jr., & Hollister, L. E. α-Methyl-p-tyrosine (AMT) in schizophrenia Psychopharmacologia, 11, 189–194, 1967.

    Article  CAS  PubMed  Google Scholar 

  31. Glassman, A. & Platman, S. R. Potentiation of a monoamine oxidase inhibitor by tryptophan. Journal of Psychiatric Research, 7, 83–88, 1969.

    Article  CAS  PubMed  Google Scholar 

  32. Goodwin, F. K., Brodie, H. K. H., Murphy, D. L., & Bunney, W. E., Jr. L-dopa, catecholamines and behavior: A clinical and biochemical study in depressed patients. Biological Psychiatry, 2, 341–366, 1970.

    CAS  PubMed  Google Scholar 

  33. Goodwin, F. K., Post, R. M., Dunner, D. L., Sc Gordon, E. K. Cerebrospinal fluid amine metabolism in affective illness: The probenecid technique. American Journal of Psychiatry, 130, 73–79, 1973.

    Article  CAS  PubMed  Google Scholar 

  34. Goodwin, F. K. Discussion remark. In: Barchas, J. D., Hamburg, D. A. and Usdin, E. (Eds.), Neuroregulators and Hypotheses of Psychiatric Disorders. Oxford University Press (in press).

    Google Scholar 

  35. Gordon, E. K., Olivier, J., Goodwin, F. K., Chase, T. N., & Post, R. M. Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid. Neuropharmacology, 12, 391–396, 1973.

    Article  CAS  PubMed  Google Scholar 

  36. Greenspan, K., Schildkraut, J. J., Gordon, E. K., Bar, L., Aronoff, M. S., & Duren, J. Catecholamine metabolism in affective disorders: III. 3-methoxy-4hydroxyphenylglycol and other catecholamine metabolites in patients treated with lithium carbonate. Journal of Psychiatric Research, 7, 171–183, 1970.

    Article  CAS  PubMed  Google Scholar 

  37. Hamberger, B. & Tuck, J. R. Effect of tricyclic antidepressants on the uptake of noradrenaline and 5-hydroxytryptamine by rat brain slices incubated in buffer or human plasma. European Journal of Clinical Pharmacology, 5, 229–235, 1973.

    Article  CAS  Google Scholar 

  38. Herrington, R. N., Bruce, A., Johnstone, E. C., & Lader, M. H. Comparative trial of 1-tryptophan and E.C.T. in severe depressive illness. Lancet, 2, 731–734, 1974.

    Article  CAS  PubMed  Google Scholar 

  39. Jimerson, D. C., Gordon, E. K., Post, R. M., & Goodwin, F. K. Central noradrenergic function in man: Vanillylmandelic acid in CSF. Brain Research, 99, 434–439, 1975.

    Article  CAS  PubMed  Google Scholar 

  40. Karoum, F., Wyatt, R., & Costa, E. Estimation of the contribution of peripheral and central noradrenergic neurons to urinary 3-methoxy-4-hydroxyphenyl glycol in the rat. Neuropharmacology, 13, 302–312, 1975.

    Google Scholar 

  41. Korf, J., Praag, H. M. van, & Sebens, J. B. Effect of intravenously administered probenecid in humans on the levels of 5-hydroxy-indoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenyl-glycol in cerebrospinal fluid. Biochemical Pharmacology, 20, 659–668, 1971.

    Article  CAS  PubMed  Google Scholar 

  42. Korf, J., Schutte, H. H., & Venema, K. A semi-automated fluorometric determination of 5-hydroxyindoles in the nanogram range. Analyt. Biochem., 53, 146–153, 1973.

    Article  CAS  PubMed  Google Scholar 

  43. Levitt, M., Spector, S., Sjoerdsma, A., Sc Udenfriend, S. Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea pig heart. Journal of Pharmacology and Experimental Therapy, 148, 1–8, 1965.

    CAS  Google Scholar 

  44. Lidbrink, P., Jonsson, G., and Fuxe, K. The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology, 10, 521–536, 1971.

    Article  CAS  PubMed  Google Scholar 

  45. Lloyd, K. J., Farley, I. J., Deck, J. H. N., & Hornykiewicz, O. Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Advances in Biochemical Psychopharmacology, 11, 387–397, 1974.

    CAS  Google Scholar 

  46. Maas, J. W., Fawcett, J. A., & Dekirmenjian, H. Catecholamine metabolism, depressive illness, and drug response. Archives of General Psychiatry, 19, 129–134, 1968.

    Article  CAS  PubMed  Google Scholar 

  47. Maas, J. W., Fawcett, J. A., Sc Dekirmenjian, H. Catecholamine metabolism, de-pressive illness, and drug response. Archives of General Psychiatry, 26, 252–262, 1972.

    Article  Google Scholar 

  48. Maas, J. W. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Archives of General Psychiatry, 32, 1357–1361, 1975.

    Article  CAS  PubMed  Google Scholar 

  49. Matussek, N., Benkert, O., Schneider, K., Otten, H., & Pohlmeier, H. Wirkung eines Decarboxylasehemmers (Ro 4-4602) in Kombination mit L-dopa aut gehemmte Depressionen. Arzneimittel-Fors., 20, 934–937, 1970.

    CAS  Google Scholar 

  50. Mendels, J., Frazer, A., Fitzgerald, R. G., Ramsey, T. A., & Stokes, J. W. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science, 175, 1380–1382, 1972.

    Article  CAS  PubMed  Google Scholar 

  51. Mendels, J., Stinnet, J. L., Burns, D., & Frazer, A. Amine precursors and depression. Archives of General Psychiatry, 32, 22–30, 1975.

    Article  CAS  PubMed  Google Scholar 

  52. Moses, S. G. 8c Robins, E. Regional distribution of norepinephrine and dopamine in brains of depressive suicides and alcoholic suicides. Psychopharmacological Communications, 1, 327–337, 1975.

    CAS  Google Scholar 

  53. Nagatsu, T., Hidaka, H., Kuzuya, H., & Takeya, K. Inhibition of dopamine-flhydroxylase by fusaric acid (5-butylpicolinic acid) in vitro and in vivo. Biochemical Pharmacology, 19, 35–44, 1970.

    Article  CAS  PubMed  Google Scholar 

  54. Papeschi, R. & McClure, D. J. Homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid of depressed patients. Archives of General Psychiatry, 25, 354–358, 1971.

    Article  CAS  PubMed  Google Scholar 

  55. Pare, C. M. B., Yeung, D. P. H., Price, K., Sc Stacey, R. S. 5-Hydroxytryptamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet, 2, 133–135, 1969.

    Article  CAS  PubMed  Google Scholar 

  56. Post, R. M., Gordon, E. K., Goodwin, F. K., & Bunney, W. E., Jr. Central norepinephrine metabolism in affective illness: MHPG in the cerebrospinal fluid. Science, 179, 1002–1003, 1973.

    Article  CAS  PubMed  Google Scholar 

  57. Praag, H. M. van. A critical investigation of the significance of monoamineoxidase inhibition as a therapeutic principle in the treatment of depression. Thesis, Utrecht, 1962.

    Google Scholar 

  58. Praag, H. M. van & Leijnse, B. Die Bedeutung der Psychopharmakologie für die klinische Psychiatrie. Systematik als notwendiger Ausgangspunkt. Nervenartzt, 34, 530–537, 1964.

    Google Scholar 

  59. Praag,, H. M. van & Leijnse, B. Neubewertung des Syndroms. Skizze einer funktionellen Pathologie. Psychiat. Neurol. Neurochir. (Amst.), 68, 50–66, 1965.

    Google Scholar 

  60. Praag, H. M. van, Uleman, A. M., Sc Spitz, J. C. The vital syndrome interview. A structured standard interview for the recognition and registration of the vital depressive symptom complex. Psychiat. Neurol. Neurochir. (Amst.), 68, 329–346, 1965.

    PubMed  Google Scholar 

  61. Praag, H. M. van. The complementary aspects in the relation between biological and psychodynamic psychiatry. Psychiatric Clinic, 2, 307–318, 1969.

    Google Scholar 

  62. Praag, H. M. van & Korf, J. L-tryptophan in depression. Lancet, 2, 612, 1970.

    Article  PubMed  Google Scholar 

  63. Praag, H. M. van & Korf, J. Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: A biochemical classification? Psychopharmacologia, 19, 148–152, 1971. (a)

    Article  PubMed  Google Scholar 

  64. Praag, H. M. van & Korf, J. Retarded depressions and the dopamine metabolism. Psychopharmacologia, 19, 199–203, 1971. (b)

    Article  PubMed  Google Scholar 

  65. Praag, H. M. van, Korf, J., Dols, L. C. W., & Schut, T. A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as an antidepressant. Psychopharmacologia, 25, 14–21, 1972.

    Article  PubMed  Google Scholar 

  66. Praag, H. M. van, Korf, J., & Schut, T. Cerebral monoamines and depression. An investigation with the probenecid technique. Archives of General Psychiatry, 28, 827–831, 1973.

    Article  PubMed  Google Scholar 

  67. Praag, H. M. van & Korf, J. 4-Chloramphetamines. Chance and trend in the development of new antidepressants. Journal of Clinical Pharmacology, 13, 3–14, 1973.

    Google Scholar 

  68. Praag, H. M. van. Towards a biochemical typology of depression? Pharmacopsychiatry, 7, 281–292, 1974.

    Article  Google Scholar 

  69. Praag, H. M. van, Burg, W. van den, Bos, E. R. H., & Dols, L. C. W. 5-Hydroxytryptophan in combination with clomipramine in “therapy-resistant” depression. Psychopharmacologia, 38, 267–269, 1974.

    Article  PubMed  Google Scholar 

  70. Praag, H. M. van & Korf, J. Central monoamine deficiency in depressions: Causative or secondary phenomenon. Pharmakopsychiat., 8, 322–326, 1975.

    Article  Google Scholar 

  71. Praag, H. M. van, Korf, J., Lakke, J. P. W. F., & Schut, T. Dopamine metabolism in depression, psychosis and Parkinson’s disease or: The problem of the specificity of biological variables in behavior disorders. Psychological Medicine, 5, 138–146, 1975.

    Google Scholar 

  72. Praag, H. M. van & Korf, J. 4-Chloramphetamines. In: Usdin, E. & Forrest, I. S. (Eds.), Psychotherapeutic Drugs. New York: Marcel Dekker, Inc., 1976.

    Google Scholar 

  73. Praag, H. M. van. Depression and Schizophrenia. A Contribution on Their Chemical Pathology. New York: Spectrum Publications, 1976.

    Google Scholar 

  74. Praag, H. M. van. About the impossible concept of schizophrenia. Comprehensive Psychiatry. In press.

    Google Scholar 

  75. Praag, H. M. van. Indoleamines in depression. In: Barchas, J. D., Hamburg, D. A. & Usdin, E. (Eds.), Neuroregulators and Hypotheses of Psychiatric Disorders. Oxford University Press, In press.

    Google Scholar 

  76. Randrup, A. & Munkvad, I. Biochemical, anatomical and psychological investigation of stereotyped behavior induced by amphetamines. In: Costa, E. & Garattini, S. (Eds.), Amphetamines and Related Compounds. New York: Raven Press, 1970.

    Google Scholar 

  77. Redmond, E. E., Jr., Maas, J. W., Kling, A., Graham, C. W., & Dekirmenjian, H. Social behavior of monkeys selectively depleted of monoamines. Science, 174, 428–430, 1971.

    Article  CAS  PubMed  Google Scholar 

  78. Roos, B-E. & Sjöstrom, R. 5-Hydroxyindoleacetic acid and homovanillic acid levels in the cerebrospinal fluid after probenecid application in patients with manic-depressive psychosis. Journal of Clinical Pharmacology, 1, 153–155, 1969.

    Article  CAS  Google Scholar 

  79. Ross, S. B. & Renyi, A. L. Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue. European Journal of Pharmacology, 7, 270–277, 1969.

    Article  CAS  PubMed  Google Scholar 

  80. Sack, R. L. & Goodwin, F. K. Inhibition of dopamine-ß-hydroxylase in manic patients. Archives of General Psychiatry, 31, 649–654, 1974.

    Article  CAS  PubMed  Google Scholar 

  81. Sano, I. L-5-hydroxytryptophan (1-5-HTP)-therapie bei endogener Depression. Munch. Med. Wschr., 144, 1713–1716, 1972.

    Google Scholar 

  82. Schildkraut, J. J. Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: Preliminary findings. American Journal of Psychiatry, 130, 695–698, 1973.

    Article  CAS  PubMed  Google Scholar 

  83. Schildkraut, J. J., Keeler, B. A., Papousek, M., & Hartmann, E. MHPG excretion in depressive disorders: Relation to clinical subtypes and desynchronized sleep. Science, 181, 762–764, 1973.

    Article  CAS  PubMed  Google Scholar 

  84. Schildkraut, J. J. Biochemical criteria for classifying depressive disorders and predicting responses to pharmacotherapy: Preliminary findings from studies of norepinephrine metabolism. Pharmacopsychiatry, 7, 98–107, 1974.

    Article  CAS  Google Scholar 

  85. Schildkraut, J. J. Depressions and biogenic amines. In: Hamburg, D. (Ed.), American Handbook of Psychiatry, V I. New York: Basic Books, 1975.

    Google Scholar 

  86. Schuckit, M., Robins, E., & Feighner, J. Tricyclic antidepressants and monoamine oxidase inhibitors. Archives of General Psychiatry, 24, 509–514, 1971.

    Article  CAS  PubMed  Google Scholar 

  87. Schutte, H. H. Het metabolisme van serotonine in rattehersenen. Studies met radioactief gemerkt tryptofaan en toepassing van computersimulatie. Thesis, Groningen, 1976.

    Google Scholar 

  88. Shaw, D. M., Camps, F. E., & Eccleston, E. G. 5-Hydroxytryptamine in hindbrain of depressive suicides. British Journal of Psychiatry, 113, 1407–1411, 1967.

    Article  CAS  PubMed  Google Scholar 

  89. Shaw, D. M., O’Keeffe, R., MacSweeney, D. A., Brooksbank, B. W. L., Noguera, R. & Coppen, A. 3-Methoxy-4-hydroxyphenylglycol in depression. Psychological Medicine, 3, 333–336, 1973.

    Article  CAS  PubMed  Google Scholar 

  90. Shields, J. Genetic factors in neurosis. In: Praag, H. M. van (Ed.), Research in Neurosis. Amsterdam: Erven Bohn, B.V., 1976.

    Google Scholar 

  91. Shopsin, B., Wilk, S., Gershon, S., Davis, K., & Suhl, M. Cerebrosipnal fluid MHPG. An assessment of norepinephrine metabolism in affective disorders. Archives of General Psychiatry, 28, 230–233, 1973.

    Article  CAS  PubMed  Google Scholar 

  92. Shopsin, B., Wilk, S., Gershon, S., Roffman, M., & Goldstein, M. Collaborative psychopharmacologic studies exploring catecholamine metabolism in psychiatric disorders. In: Usdin, E. & Snyder, S. (Eds.), Frontiers in Catecholamine Research. New York: Pergamon Press, 1973, pp. 1173–1179.

    Chapter  Google Scholar 

  93. Shopsin, B., Gershon, S., Goldstein, M., Friedman, E., & Wilk, S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacological Communications, 1, 239–249, 1975.

    CAS  Google Scholar 

  94. Sjöström, R. & Roos, B-E. 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis. European Journal of Clinical Pharmacology, 4, 170–176, 1972.

    Article  Google Scholar 

  95. Takahashi, S., Kondo, H., & Kato, N. Effect of 1-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effects in depressed patients. Journal of Psychiatric Research, 12, 177–187.

    Google Scholar 

  96. Trimble, M., Chadwick, D., Reynolds, E. H., & Marsden, C. D. L-5-hydroxytryptophan and mood. Lancet, 1, 583, 1975.

    Article  CAS  PubMed  Google Scholar 

  97. Tuck, J. R. & Punell, G. Uptake of (3H) 5-hydroxytryptamine and (3H) noradrenaline by slices of rat brain incubated in plasma from patients treated with chlorimipramine, or amitriptyline. J. Pharm. Pharmacol., 25, 573–574, 1973.

    Article  CAS  PubMed  Google Scholar 

  98. WÂlinder, J., Skott, A., Nagy, A., Carlsson, A., & Roos, B-E. Potentiation of antidepressant action of clomipramine by tryptophan. Lancet, 1, 984, 1975.

    Article  PubMed  Google Scholar 

  99. Westerink, B. H. C. & Korf, J. Determination of nanogram amounts of homovanillic acid in the central nervous system with a rapid semi-automated fluorometric method. Biochemical Medicine, 12, 106–115, 1975.

    Article  CAS  PubMed  Google Scholar 

  100. Wilk, S., Davis, K. L., Sc Thackes, S. B. Determination of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) in cerebrospinal fluid. Analytical Biochemistry, 39, 498–504, 1971.

    Article  CAS  PubMed  Google Scholar 

  101. Wilk, S., Shopsin, B., Gershon, S., Sc Suhl, M. Cerebrospinal fluid levels of MHPG in affective disorders. Nature, 235, 440–441, 1972.

    Article  CAS  PubMed  Google Scholar 

  102. Wilk, S. Metabolism of biogenic amines in the central nervous system of man. Paper read at the Sixth International Congress of Pharmacology, Helsinski, 1975.

    Google Scholar 

Download references

Authors
  1. H. M. van Praag M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry, University of Toronto, Canada

    Vivian M. Rakoff M.A., M.B.B.S., F.R.C.P.(C) (Professor of Psychiatric Education), Harvey C. Stancer Ph.D., M.D., F.R.C.P.(C) (Professor of Psychiatric Research) & Henry B. Kedward M.A., M.D., F.R.C.P.(C) (Professor) (Professor of Psychiatric Education),  (Professor of Psychiatric Research) &  (Professor)

Copyright information

© 1977 Brunner/Mazel, Inc.

About this chapter

Cite this chapter

van Praag, H.M. (1977). The Vulnerable Brain: Biological Factors in the Diagnosis and Treatment of Depression. In: Rakoff, V.M., Stancer, H.C., Kedward, H.B. (eds) Psychiatric Diagnosis. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-03753-7_8

Download citation

Publish with us

Policies and ethics

Search

Navigation